2VT0 Stock Overview
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Lipocine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.67 |
| 52 Week High | US$11.98 |
| 52 Week Low | US$3.25 |
| Beta | 0.96 |
| 1 Month Change | 0% |
| 3 Month Change | 8.00% |
| 1 Year Change | -69.34% |
| 3 Year Change | -87.87% |
| 5 Year Change | -85.21% |
| Change since IPO | -96.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2VT0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 0.5% |
| 1Y | -69.3% | -28.6% | 1.3% |
Return vs Industry: 2VT0 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 2VT0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 2VT0 volatility | |
|---|---|
| 2VT0 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2VT0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2VT0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 17 | Mahesh Patel | www.lipocine.com |
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis.
Lipocine Inc. Fundamentals Summary
| 2VT0 fundamental statistics | |
|---|---|
| Market cap | €23.82m |
| Earnings (TTM) | -€10.17m |
| Revenue (TTM) | €506.76k |
47.5x
P/S Ratio-2.4x
P/E RatioIs 2VT0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2VT0 income statement (TTM) | |
|---|---|
| Revenue | US$554.99k |
| Cost of Revenue | US$0 |
| Gross Profit | US$554.99k |
| Other Expenses | US$11.70m |
| Earnings | -US$11.14m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.14 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,007.45% |
| Debt/Equity Ratio | 0% |
How did 2VT0 perform over the long term?
See historical performance and comparison